Lymphoid Highlights from BSH 2017
Myeloma 2016: Panel discussion on the application of genomics studies
Leif Bergsagel et al.
Minimal residual disease (MRD) as a prognostic factor for acute myeloid leukemia (AML)
Gerrit Jan Schuurhuis
Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele